+101.3%
HIMS vs GSK
+69.3%
+32.0%
-87.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | +0.5% | -0.5% | -0.1% |
| 7D | -24.1% | +1.1% | -25.3% | -24.2% |
| 30D | -28.8% | +6.3% | -35.2% | -29.3% |
| 3M | -31.4% | +1.8% | -33.2% | -31.6% |
| 6M | -18.3% | +1.7% | -19.9% | -18.7% |
| YTD | -39.2% | +6.5% | -45.8% | -40.0% |
| 1Y | -45.3% | +9.5% | -54.8% | -46.2% |
| 3Y | +181.9% | +65.3% | +116.6% | +150.9% |
| 5Y | +166.6% | +43.7% | +122.9% | +140.1% |
| All | +101.3% | +69.3% | +32.0% | +77.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling